Fusion Polymerase and Method for Using the Same
US-2016160193-A1 · Jun 9, 2016 · US
Mutant reverse transcriptase
US9580698B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9580698-B1 |
| Application number | US-201615274622-A |
| Country | US |
| Kind code | B1 |
| Filing date | Sep 23, 2016 |
| Priority date | Sep 23, 2016 |
| Publication date | Feb 28, 2017 |
| Grant date | Feb 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A mutant MMLV reverse transcriptase that may have an improvement in one or more properties is provided. For example, the present reverse transcriptase is believed to be more efficient relative to other commercially available MMLV reverse transcriptase variants, particularly for templates with a higher GC content.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide comprising at least 300 contiguous amino acids of SEQ ID NO:1. 2. The polypeptide of claim 1 , wherein the polypeptide comprises amino acid residues 24-335 of SEQ ID NO:1. 3. The polypeptide of claim 1 , wherein the polypeptide comprises a truncated N-terminus relative to SEQ ID NO:1. 4. The polypeptide of claim 1 , wherein the polypeptide comprises the entire contiguous sequence of SEQ ID NO:1. 5. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to at least 300 contiguous amino acids of SEQ ID NO:2 that is C-terminal to the at least 300 contiguous amino acids of SEQ ID NO:1. 6. The polypeptide of claim 5 , wherein the polypeptide comprises an exogenous sequence-specific DNA binding domain. 7. The polypeptide of claim 5 , wherein the polypeptide comprises a purification tag. 8. The polypeptide of claim 5 , wherein the polypeptide has reverse transcriptase activity. 9. The polypeptide of claim 8 , wherein the polypeptide does not have RNAseH activity. 10. The polypeptide of claim 8 , wherein the polypeptide has RNAseH activity.
Assignees
Inventors
Classifications
RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title
- C12N9/1276Primary
RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase · CPC title
Ribonuclease H (3.1.26.4) · CPC title
Polymerase chain reaction [PCR] · CPC title
Polynucleotides, e.g. nucleic acids, oligoribonucleotides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9580698B1 cover?
- A mutant MMLV reverse transcriptase that may have an improvement in one or more properties is provided. For example, the present reverse transcriptase is believed to be more efficient relative to other commercially available MMLV reverse transcriptase variants, particularly for templates with a higher GC content.
- Who is the assignee on this patent?
- New England Biolabs Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1276. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).